Safety profile of a liquid formulation of deferiprone (GPO-L-ONE) in thalassemia children with transfusion-induced iron overload: pilot study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20170907001

Enrollment

Registered

2017-09-07

Start date

2017-08-16

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with thalassemia disease&#44

Interventions

A liquid formulation of deferiprone

Children with thalassemia disease&#44

age equal to or more than two years of age

No Intervention Drug

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: Male & female age minimum 2 years, maximum 12 years

Exclusion criteria

Exclusion criteria: 1. Patients exhibit an anaphylaxis to deferriprone 2. Iron overload from other causes 3. Serum ferritin >7,000 ng/ml 4. ALT > 250 IU/L 5. Elevated creatinine for age 6. Absolute neutrophil <500/uL

Design outcomes

Primary

Measure	Time frame
Safety profile of a liquid formulation of deferiprone (GPO-L-ONE) Monthly Number of neutrophil	—

Secondary

Measure	Time frame
Efficacy of a liquid formulation of deferiprone (GPO-L-ONE) Monthly Declination of serum ferritin >15% from baseline	—

Countries

Thailand

Contacts

Public ContactAmpaiwan Chuansumrit

Faculty of Medicine Ramathibodi Hospital, Mahidol University

ampaiwan.jua@mahidol.ac.th0818338494

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Safety profile of a liquid formulation of deferiprone (GPO&#45;L&#45;ONE) in thalassemia children with transfusion&#45;induced iron overload: pilot study